Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Brokerages

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight analysts that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $20.00.

ALT has been the subject of several recent analyst reports. UBS Group started coverage on shares of Altimmune in a research note on Tuesday, November 12th. They issued a "buy" rating and a $26.00 target price for the company. HC Wainwright reissued a "buy" rating and set a $12.00 target price on shares of Altimmune in a report on Thursday, November 14th.

Institutional Trading of Altimmune

Several institutional investors have recently added to or reduced their stakes in ALT. Bellevue Group AG grew its position in shares of Altimmune by 43.9% during the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company's stock worth $5,303,000 after purchasing an additional 263,660 shares in the last quarter. SG Americas Securities LLC increased its stake in Altimmune by 542.8% during the 2nd quarter. SG Americas Securities LLC now owns 254,571 shares of the company's stock worth $1,693,000 after acquiring an additional 214,968 shares during the period. Dimensional Fund Advisors LP raised its holdings in Altimmune by 142.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company's stock valued at $3,791,000 after acquiring an additional 335,444 shares in the last quarter. Hennion & Walsh Asset Management Inc. bought a new stake in shares of Altimmune during the 2nd quarter valued at $860,000. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Altimmune during the 2nd quarter worth $689,000. 78.05% of the stock is currently owned by institutional investors.

Altimmune Trading Up 5.1 %

Shares of NASDAQ ALT traded up $0.44 during midday trading on Friday, reaching $9.03. The company's stock had a trading volume of 3,005,469 shares, compared to its average volume of 3,839,838. The stock has a market capitalization of $642.26 million, a price-to-earnings ratio of -5.55 and a beta of 0.15. Altimmune has a fifty-two week low of $5.28 and a fifty-two week high of $14.84. The stock has a 50 day simple moving average of $7.65 and a 200-day simple moving average of $7.05.

Altimmune (NASDAQ:ALT - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The company had revenue of $0.01 million during the quarter. During the same quarter in the previous year, the business earned ($0.39) EPS. As a group, equities analysts anticipate that Altimmune will post -1.36 EPS for the current year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.